RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.

Never miss a new study

Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear

Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 8 Not yet recruiting 2 Not yet finished but already full! 1

Experimental drug combo targets recurrent brain cancer

Disease control Terminated

This early-stage trial tests the safety and best dose of a drug called triapine when given with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that help cancer cells grow, while radiation uses high-energy beams to …

Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 14:01 UTC

RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear

Experimental drug combo targets recurrent brain cancer